APO Research
Talk to an analyst

APO RESEARCH · REPORT

Autoimmune and Inflammatory Immunomodulators

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Autoimmune and Inflammatory Immunomodulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchAutoimmune and Inflammatory Immunomodulators Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Autoimmune and Inflammatory Immunomodulators Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Autoimmune and Inflammatory Immunomodulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Autoimmune and Inflammatory Immunomodulators Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Autoimmune and Inflammatory Immunomodulators Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Autoimmune and Inflammatory Immunomodulators market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Autoimmune and Inflammatory Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Autoimmune and Inflammatory Immunomodulators include Johnson & Johnson, Eli Lilly, Pfizer, Amgen, AbbVie, AstraZeneca, Gilead Sciences, F. Hoffmann-La Roche and Enlivex Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Autoimmune and Inflammatory Immunomodulators market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Autoimmune and Inflammatory Immunomodulators and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Autoimmune and Inflammatory Immunomodulators sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Autoimmune and Inflammatory Immunomodulators market size, projected growth trends, production technologies, key applications, and end-use industries.

Autoimmune and Inflammatory Immunomodulators Segment by Company

Johnson & Johnson

Eli Lilly

Pfizer

Amgen

AbbVie

AstraZeneca

Gilead Sciences

F. Hoffmann-La Roche

Enlivex Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Biogen Idec

Avaxia Biologics

Autoimmune and Inflammatory Immunomodulators Segment by Type

Biologics

Small Molecules

Autoimmune and Inflammatory Immunomodulators Segment by Application

Rheumatoid Arthritis

IBD

Autoimmune and Inflammatory Immunomodulators Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autoimmune and Inflammatory Immunomodulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Autoimmune and Inflammatory Immunomodulators and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autoimmune and Inflammatory Immunomodulators.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Autoimmune and Inflammatory Immunomodulators market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Autoimmune and Inflammatory Immunomodulators manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Autoimmune and Inflammatory Immunomodulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Autoimmune and Inflammatory Immunomodulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Autoimmune and Inflammatory Immunomodulators Industry Trends Table 2. Autoimmune and Inflammatory Immunomodulators Industry Drivers Table 3. Autoimmune and Inflammatory Immunomodulators Industry Opportunities and Challenges Table 4. Autoimmune and Inflammatory Immunomodulators Industry Restraints Table 5. Global Autoimmune and Inflammatory Immunomodulators Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Autoimmune and Inflammatory Immunomodulators Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Manufacturers Table 9. Global Autoimmune and Inflammatory Immunomodulators Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Autoimmune and Inflammatory Immunomodulators Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Autoimmune and Inflammatory Immunomodulators Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Autoimmune and Inflammatory Immunomodulators Manufacturers, Product Type & Application Table 13. Global Autoimmune and Inflammatory Immunomodulators Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Autoimmune and Inflammatory Immunomodulators by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Biologics Table 17. Major Manufacturers of Small Molecules Table 18. Global Autoimmune and Inflammatory Immunomodulators Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 19. Global Autoimmune and Inflammatory Immunomodulators Sales by Type (2021-2026) & (W Units) Table 20. Global Autoimmune and Inflammatory Immunomodulators Sales by Type (2027-2032) & (W Units) Table 21. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Type (2021-2026) Table 22. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Type (2027-2032) Table 23. Global Autoimmune and Inflammatory Immunomodulators Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Autoimmune and Inflammatory Immunomodulators Revenue by Type (2021-2026) & (W Units) Table 25. Global Autoimmune and Inflammatory Immunomodulators Revenue by Type (2027-2032) & (W Units) Table 26. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Type (2021-2026) Table 27. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Rheumatoid Arthritis Table 29. Major Manufacturers of IBD Table 30. Global Autoimmune and Inflammatory Immunomodulators Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 31. Global Autoimmune and Inflammatory Immunomodulators Sales by Application (2021-2026) & (W Units) Table 32. Global Autoimmune and Inflammatory Immunomodulators Sales by Application (2027-2032) & (W Units) Table 33. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Application (2021-2026) Table 34. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Application (2027-2032) Table 35. Global Autoimmune and Inflammatory Immunomodulators Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Autoimmune and Inflammatory Immunomodulators Revenue by Application (2021-2026) & (W Units) Table 37. Global Autoimmune and Inflammatory Immunomodulators Revenue by Application (2027-2032) & (W Units) Table 38. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Application (2021-2026) Table 39. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Application (2027-2032) Table 40. Global Autoimmune and Inflammatory Immunomodulators Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 41. Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2021-2026) & (W Units) Table 42. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Region (2021-2026) Table 43. Global Autoimmune and Inflammatory Immunomodulators Sales Forecasted by Region (2027-2032) & (W Units) Table 44. Global Autoimmune and Inflammatory Immunomodulators Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 46. North America Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2026) & (W Units) Table 47. North America Autoimmune and Inflammatory Immunomodulators Sales by Country (2027-2032) & (W Units) Table 48. Europe Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. Europe Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2026) & (W Units) Table 50. Europe Autoimmune and Inflammatory Immunomodulators Sales by Country (2027-2032) & (W Units) Table 51. Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2026) & (W Units) Table 53. Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales by Country (2027-2032) & (W Units) Table 54. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2026) & (W Units) Table 56. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales by Country (2027-2032) & (W Units) Table 57. Global Autoimmune and Inflammatory Immunomodulators Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Autoimmune and Inflammatory Immunomodulators Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Autoimmune and Inflammatory Immunomodulators Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Region (2021-2026) Table 61. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Region (2027-2032) Table 62. Johnson & Johnson Company Information Table 63. Johnson & Johnson Business Overview Table 64. Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 66. Johnson & Johnson Recent Development Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Eli Lilly Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 71. Eli Lilly Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Pfizer Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 76. Pfizer Recent Development Table 77. Amgen Company Information Table 78. Amgen Business Overview Table 79. Amgen Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Amgen Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 81. Amgen Recent Development Table 82. AbbVie Company Information Table 83. AbbVie Business Overview Table 84. AbbVie Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. AbbVie Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 86. AbbVie Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AstraZeneca Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Gilead Sciences Company Information Table 93. Gilead Sciences Business Overview Table 94. Gilead Sciences Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Gilead Sciences Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 96. Gilead Sciences Recent Development Table 97. F. Hoffmann-La Roche Company Information Table 98. F. Hoffmann-La Roche Business Overview Table 99. F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 101. F. Hoffmann-La Roche Recent Development Table 102. Enlivex Therapeutics Company Information Table 103. Enlivex Therapeutics Business Overview Table 104. Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 106. Enlivex Therapeutics Recent Development Table 107. Bristol-Myers Squibb Company Information Table 108. Bristol-Myers Squibb Business Overview Table 109. Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 111. Bristol-Myers Squibb Recent Development Table 112. Boehringer Ingelheim Company Information Table 113. Boehringer Ingelheim Business Overview Table 114. Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 116. Boehringer Ingelheim Recent Development Table 117. Biogen Idec Company Information Table 118. Biogen Idec Business Overview Table 119. Biogen Idec Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Biogen Idec Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 121. Biogen Idec Recent Development Table 122. Avaxia Biologics Company Information Table 123. Avaxia Biologics Business Overview Table 124. Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Product Portfolio Table 126. Avaxia Biologics Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Autoimmune and Inflammatory Immunomodulators Distributors List Table 130. Autoimmune and Inflammatory Immunomodulators Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Autoimmune and Inflammatory Immunomodulators Product Image Figure 2. Global Autoimmune and Inflammatory Immunomodulators Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Autoimmune and Inflammatory Immunomodulators Market Size (2021-2032) & (US$ Million) Figure 4. Global Autoimmune and Inflammatory Immunomodulators Sales (2021-2032) & (W Units) Figure 5. Global Autoimmune and Inflammatory Immunomodulators Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Autoimmune and Inflammatory Immunomodulators Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Biologics Image Figure 9. Small Molecules Image Figure 10. Global Autoimmune and Inflammatory Immunomodulators Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 11. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Type (2021-2032) Figure 13. Global Autoimmune and Inflammatory Immunomodulators Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Type (2021-2032) Figure 16. Rheumatoid Arthritis Image Figure 17. IBD Image Figure 18. Global Autoimmune and Inflammatory Immunomodulators Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 19. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Application (2021-2032) Figure 21. Global Autoimmune and Inflammatory Immunomodulators Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Application (2021-2032) Figure 24. North America Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 25. North America Autoimmune and Inflammatory Immunomodulators Sales Market Share by Country (2021-2032) Figure 26. U.S. Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 27. Canada Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 28. Mexico Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Europe Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Europe Autoimmune and Inflammatory Immunomodulators Sales Market Share by Country (2021-2032) Figure 31. Germany Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 32. France Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 33. U.K. Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Italy Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Netherlands Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales Market Share by Country (2021-2032) Figure 38. China Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Japan Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 40. South Korea Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Southeast Asia Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 42. India Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Australia Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales Market Share by Country (2021-2032) Figure 46. Brazil Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South Africa Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Saudi Arabia Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Turkey Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Argentina Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 51. UAE Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Egypt Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Chile Autoimmune and Inflammatory Immunomodulators Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Global Autoimmune and Inflammatory Immunomodulators Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032) & (US$ Million) Figure 57. North America Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032) & (US$ Million) Figure 59. Europe Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Autoimmune and Inflammatory Immunomodulators Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Autoimmune and Inflammatory Immunomodulators Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Small Molecules
Applications
  • Rheumatoid Arthritis
  • IBD
Companies covered
  • Johnson & Johnson
  • Eli Lilly
  • Pfizer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Gilead Sciences
  • F. Hoffmann-La Roche
  • Enlivex Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Biogen Idec
  • Avaxia Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Autoimmune and Inflammatory Immunomodulators Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Autoimmune and Inflammatory Immunomodulators Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Autoimmune and Inflammatory Immunomodulators Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Autoimmune and Inflammatory Immunomodulators Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Autoimmune and Inflammatory Immunomodulators Market Dynamics
  1. 2.1 Autoimmune and Inflammatory Immunomodulators Industry Trends
  2. 2.2 Autoimmune and Inflammatory Immunomodulators Industry Drivers
  3. 2.3 Autoimmune and Inflammatory Immunomodulators Industry Opportunities and Challenges
  4. 2.4 Autoimmune and Inflammatory Immunomodulators Industry Restraints
3 Autoimmune and Inflammatory Immunomodulators Market by Manufacturers
  1. 3.1 Global Autoimmune and Inflammatory Immunomodulators Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Manufacturers (2021-2026)
  3. 3.3 Global Autoimmune and Inflammatory Immunomodulators Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Autoimmune and Inflammatory Immunomodulators Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Autoimmune and Inflammatory Immunomodulators Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Autoimmune and Inflammatory Immunomodulators Manufacturers, Product Type & Application
  7. 3.7 Global Autoimmune and Inflammatory Immunomodulators Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Autoimmune and Inflammatory Immunomodulators Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Autoimmune and Inflammatory Immunomodulators Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Autoimmune and Inflammatory Immunomodulators Tier 1, Tier 2, and Tier 3
4 Autoimmune and Inflammatory Immunomodulators Market by Type
  1. 4.1 Autoimmune and Inflammatory Immunomodulators Type Introduction
  2. 4.1.1 Biologics
  3. 4.1.2 Small Molecules
  4. 4.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Type
  5. 4.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Type (2021-2032)
  7. 4.2.3 Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Type (2021-2032)
  8. 4.3 Global Autoimmune and Inflammatory Immunomodulators Revenue by Type
  9. 4.3.1 Global Autoimmune and Inflammatory Immunomodulators Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Autoimmune and Inflammatory Immunomodulators Revenue by Type (2021-2032)
  11. 4.3.3 Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Type (2021-2032)
5 Autoimmune and Inflammatory Immunomodulators Market by Application
  1. 5.1 Autoimmune and Inflammatory Immunomodulators Application Introduction
  2. 5.1.1 Rheumatoid Arthritis
  3. 5.1.2 IBD
  4. 5.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Application
  5. 5.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Application (2021-2032)
  7. 5.2.3 Global Autoimmune and Inflammatory Immunomodulators Sales Market Share by Application (2021-2032)
  8. 5.3 Global Autoimmune and Inflammatory Immunomodulators Revenue by Application
  9. 5.3.1 Global Autoimmune and Inflammatory Immunomodulators Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Autoimmune and Inflammatory Immunomodulators Revenue by Application (2021-2032)
  11. 5.3.3 Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Application (2021-2032)
6 Global Autoimmune and Inflammatory Immunomodulators Sales by Region
  1. 6.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2021-2032)
  3. 6.2.1 Global Autoimmune and Inflammatory Immunomodulators Sales by Region (2021-2026)
  4. 6.2.2 Global Autoimmune and Inflammatory Immunomodulators Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Autoimmune and Inflammatory Immunomodulators Revenue by Region
  1. 7.1 Global Autoimmune and Inflammatory Immunomodulators Revenue by Region
  2. 7.1.1 Global Autoimmune and Inflammatory Immunomodulators Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Autoimmune and Inflammatory Immunomodulators Revenue by Region (2021-2026)
  4. 7.1.3 Global Autoimmune and Inflammatory Immunomodulators Revenue by Region (2027-2032)
  5. 7.1.4 Global Autoimmune and Inflammatory Immunomodulators Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032)
  8. 7.2.2 North America Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032)
  11. 7.3.2 Europe Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Autoimmune and Inflammatory Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Autoimmune and Inflammatory Immunomodulators Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Autoimmune and Inflammatory Immunomodulators Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Autoimmune and Inflammatory Immunomodulators Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Autoimmune and Inflammatory Immunomodulators Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Autoimmune and Inflammatory Immunomodulators Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Autoimmune and Inflammatory Immunomodulators Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Gilead Sciences
  38. 8.7.1 Gilead Sciences Company Information
  39. 8.7.2 Gilead Sciences Business Overview
  40. 8.7.3 Gilead Sciences Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Sciences Autoimmune and Inflammatory Immunomodulators Product Portfolio
  42. 8.7.5 Gilead Sciences Recent Developments
  43. 8.8 F. Hoffmann-La Roche
  44. 8.8.1 F. Hoffmann-La Roche Company Information
  45. 8.8.2 F. Hoffmann-La Roche Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Autoimmune and Inflammatory Immunomodulators Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Recent Developments
  49. 8.9 Enlivex Therapeutics
  50. 8.9.1 Enlivex Therapeutics Company Information
  51. 8.9.2 Enlivex Therapeutics Business Overview
  52. 8.9.3 Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Enlivex Therapeutics Autoimmune and Inflammatory Immunomodulators Product Portfolio
  54. 8.9.5 Enlivex Therapeutics Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Autoimmune and Inflammatory Immunomodulators Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Autoimmune and Inflammatory Immunomodulators Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Biogen Idec
  68. 8.12.1 Biogen Idec Company Information
  69. 8.12.2 Biogen Idec Business Overview
  70. 8.12.3 Biogen Idec Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Biogen Idec Autoimmune and Inflammatory Immunomodulators Product Portfolio
  72. 8.12.5 Biogen Idec Recent Developments
  73. 8.13 Avaxia Biologics
  74. 8.13.1 Avaxia Biologics Company Information
  75. 8.13.2 Avaxia Biologics Business Overview
  76. 8.13.3 Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Avaxia Biologics Autoimmune and Inflammatory Immunomodulators Product Portfolio
  78. 8.13.5 Avaxia Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Autoimmune and Inflammatory Immunomodulators Value Chain Analysis
  2. 9.1.1 Autoimmune and Inflammatory Immunomodulators Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Autoimmune and Inflammatory Immunomodulators Production Mode & Process
  6. 9.2 Autoimmune and Inflammatory Immunomodulators Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Autoimmune and Inflammatory Immunomodulators Distributors
  9. 9.2.3 Autoimmune and Inflammatory Immunomodulators Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst